SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Care-plan review) — Harriet Tubman

PatientHarriet Tubman
Date of birth1951-03-01
IdentifiersMRN HR-NI005-SYN; SSN (made up) 000-05-3961
Document date2026-08-17
AuthorCarmen Ruiz-Delgado, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month sleepiness and headache review. [S]

History of Present Illness

Mrs. Tubman returns three months after starting modafinil and increasing candesartan to 16 mg. She takes modafinil each morning and two scheduled 15-minute naps, and unplanned sleep episodes are now rare, only while seated. Her headache diary shows 21 headache days in the past three months, against 54 before treatment. She uses acetaminophen about once a week and has taken no ibuprofen. She has had no palpitations, insomnia, or loss of appetite on modafinil and no dizziness on candesartan. She is back to running her household and her church work. [S]

ElementDetail
Sleep episodesRare and only while seated, with two planned naps a day
Headache diary21 headache days in three months, down from 54
Acute medicineAcetaminophen about once a week; no ibuprofen
Medication toleranceNo palpitations, insomnia, or appetite loss on modafinil; no dizziness on candesartan
FunctionRunning her household and church work again

Review of Systems

SystemResultFinding
NeurologicalPositiveHeadaches about seven days a month; rare sleep episodes
CardiovascularNegativeNo palpitations, chest pain, or light-headedness
GastrointestinalNegativeAppetite normal; no nausea
PsychiatricNegativeMood good; no anxiety or insomnia; PHQ-9 score 2

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ibuprofen 200 mg oral tablet, two tablets by mouth most days (self-directed, over the counter)Two tablets by mouth most daysOral route2025-09-01 to 2026-04-06stoppedS
Acetaminophen 500 mg oral tablet, two tablets by mouth as needed for headache, no more than 2 days a weekTwo tablets by mouth as needed, at most 2 days a weekOral route2026-04-06activeS
Candesartan 8 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-20 to 2026-05-18completedS
Candesartan 16 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-18activeS
Modafinil 100 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-05-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-17Body height152cmS
2026-08-17Body weight51.5kgS
2026-08-17Body mass index (BMI) [Ratio]22.3kg/m2S
2026-08-17Systolic blood pressure124mm[Hg]S
2026-08-17Diastolic blood pressure74mm[Hg]S
2026-08-17Heart rate76/minS
2026-08-17Respiratory rate14/minS
2026-08-17Body temperature36.6CelS
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-17Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-08-17Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-08-17Creatinine [Mass/volume] in Serum or Plasma0.88mg/dL0.59-1.04 mg/dLNormalS
2026-08-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M68mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-17Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2026-08-17PROMIS sleep related impairment - version 1.0 Tscore55{score}S
2026-08-17On how many days in the last 3 months did you have a headache, if headache lasted more than 1 day, count each day [PhenX]21{days}S
2026-08-17Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S

Physical Exam

Vital signs recorded on 2026-08-17; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and well; no spell during the visit
CardiovascularRegular rhythm; no edema
NeurologicalNonfocal; gait normal

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent sudden sleep episodes since an adolescent traumatic brain injury; narcolepsy without cataplexy due to a medical condition, provisional; historical cause retrospectively disputedactiveprovisional G47.429S — Synthetic diagnosis from the modern sleep testing; it echoes, but does not confirm, the R proposal of post-traumatic narcolepsy.
Chronic post-traumatic headache since an adolescent head injuryactiveconfirmed G44.329S — Synthetic modern coding of the documented lifelong headaches.
Medication-overuse headache from near-daily ibuprofen, resolved after withdrawalresolvedconfirmed G44.40S — Synthetic finding; resolved by the three-month review.
Sequelae of a traumatic brain injury in adolescence, a skull fracture by historical accountactiveconfirmed S06.9XASS — Synthetic modern coding of the documented injury; the MRI findings in the episode are synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPROMIS sleep-related impairmentAt baseline and after treatmentCompleted todayT-score 55, down 13 points from baseline
Medication safetyModafinil: blood pressure and heart rateBefore starting and at follow-upCompleted today124/74 mmHg and pulse 76, against 132/80 and 72 before starting
SurveyHeadache days per three months2 to 3 months after starting preventionCompleted today21, down from 54
LaboratoryBasic metabolic panel (potassium and creatinine) on candesartanBefore starting and a few weeks after; then periodicallyCompleted todayPotassium 4.5, creatinine 0.88, eGFR 68, sodium and glucose normal
LaboratoryPotassium and creatinine after the candesartan dose increaseA few weeks after a dose increaseDeferredNot drawn after the dose was doubled three months ago, a gap in usual practice for angiotensin receptor blockers. Today's potassium and creatinine are normal, so no harm resulted. Future dose changes will carry a check in two to four weeks
ExaminationBlood pressure, heart rate, and weightEvery visitCompleted today124/74 mmHg, pulse 76, weight 51.5 kg
Self-managementHeadache diary (headache days and acute-medicine days)DailyCompleted todayReviewed; about seven headache days a month
Medication safetyAcute headache medicine on no more than 2 days a weekEvery visitCompleted todayAcetaminophen about once a week; no NSAIDs
SurveyDepression screen (PHQ-9)At baseline and at follow-upCompleted todayScore 2
Self-managementSafety advice for sudden sleep episodesEvery visitCompleted todayReviewed; no episodes while standing, walking, or cooking since starting modafinil

Goal progress:

Guideline basis: Evidence-based guideline: Management of an unprovoked first seizure in adults (Krumholz A, et al. Neurology 2015;84(16):1705-1713) (2015); Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline (Maski K, et al. J Clin Sleep Med 2021;17(9):1881-1893) (2021); The International Classification of Headache Disorders, 3rd edition (Cephalalgia 2018;38(1):1-211) (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (Ailani J, et al. Headache 2021;61(7):1021-1039) (2021)

Follow-up: Annual wellness visit in the fall. Continue the headache diary and scheduled naps. Next scheduled visit 2026-10-13: subsequent annual wellness visit. [S]